Global TROP-2 Targeted Therapy Market Projected to Reach $3.29 Billion by 2031, Driven by ADC Innovation and Rising Cancer Prevalence
核心洞察
The global TROP-2 (搜索) targeted therapy market is forecast to grow from USD 2.18 billion in 2026 to USD 3.29 billion by 2031, reflecting an 8.6% compound annual growth rate.
Antibody-drug conjugates (ADCs) dominate the therapeutic landscape, with Gilead's sacituzumab govitecan (Trodelvy) approved and AstraZeneca/Daiichi Sankyo's datopotamab deruxtecan in late-stage development.
Rising incidence of TROP-2 (搜索)-expressing cancers — including triple-negative breast cancer (搜索), non-small cell lung cancer (搜索), and urothelial carcinoma (搜索) — is a primary market driver.
The global market for TROP-2 (搜索) targeted therapies is on track to reach USD 3.29 billion by 2031, climbing from an estimated USD 2.18 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%, according to a new strategic market report from ResearchAndMarkets.com. The expansion reflects intensifying investment by biotechnology and pharmaceutical companies in therapies directed at trophoblast cell surface antigen 2 (TROP-2), a transmembrane glycoprotein overexpressed across a broad range of epithelial cancers.
TROP-2 (搜索) has emerged as a compelling oncology target due to its high expression in difficult-to-treat malignancies, including triple-negative breast cancer (搜索) (TNBC), hormone receptor-positive/HER2-negative breast cancer, non-small cell lung cancer (搜索) (NSCLC), small cell lung cancer, urothelial carcinoma (搜索), and other solid tumors such as endometrial, pancreatic, and gastrointestinal cancers. The growing global cancer burden in these indications is fueling demand for therapies that can selectively target malignant cells while minimizing damage to healthy tissue.
ADCs Dominate the Therapeutic Landscape
Antibody-drug conjugates currently represent the dominant modality within the TROP-2 (搜索) targeted therapy market, a position attributed to their strong clinical efficacy and established regulatory approvals. ADCs combine the targeting specificity of monoclonal antibodies with potent cytotoxic payloads, linked via engineered linker technologies that control drug release.
Gilead Sciences holds the only currently approved TROP-2 (搜索)-directed ADC, sacituzumab govitecan (Trodelvy), which has secured indications across multiple tumor types. AstraZeneca and Daiichi Sankyo are advancing datopotamab deruxtecan, a late-stage pipeline candidate, through Phase III clinical development. Other companies with verified TROP-2 pipeline programs include Merck & Co. (搜索), F. Hoffmann-La Roche, Pfizer, BioNTech, BeiGene, Sichuan Kelun Pharmaceutical, and Lepu Biopharma.
Precision Medicine and AI Reshape Development
The report highlights that the growing emphasis on precision medicine and biomarker-driven oncology is accelerating adoption of TROP-2 (搜索) targeted therapies. Biomarker-based patient stratification, including TROP-2 expression testing and companion diagnostics, is enabling more personalized treatment approaches and improving therapeutic success rates.
Artificial intelligence and computational biology are playing an increasingly prominent role in therapy development, aiding genomic analysis, target identification, and clinical trial optimization. These technologies are enhancing the precision oncology paradigm by enabling tailored therapeutic solutions based on individual tumor biology.
Combination therapy strategies are also gaining traction across the field. Investigators are exploring TROP-2 (搜索) ADCs in combination with immune checkpoint inhibitors and other targeted molecules, aiming to enhance anti-tumor responses and overcome resistance mechanisms.
Market Drivers and Restraints
The primary growth drivers identified in the report include the rising global incidence of TROP-2 (搜索)-expressing cancers, advancements in ADC technology that improve therapeutic precision and safety, and the broader shift toward personalized medicine. The demonstrated ability of TROP-2 therapies to improve patient outcomes in challenging settings such as TNBC and metastatic urothelial carcinoma (搜索) continues to fuel clinical and commercial interest.
However, the market faces significant headwinds. The high cost of ADC therapies presents barriers to widespread adoption, while safety and toxicity concerns — notably neutropenia and diarrhea — require careful clinical management. Regulatory complexity and limited biomarker standardization further complicate market growth. Manufacturing complexity inherent to ADCs adds another layer of operational challenge for developers.
Regional Dynamics and Competitive Outlook
North America currently leads the global TROP-2 (搜索) targeted therapy market, supported by advanced healthcare infrastructure, a robust biotechnology ecosystem, and the United States' central role in ADC research and commercialization. Europe represents a significant market driven by precision oncology initiatives. The Asia-Pacific region is forecast for the most rapid expansion, propelled by rising cancer prevalence and ongoing healthcare infrastructure advancements.
The competitive landscape features major pharmaceutical players pursuing ADC innovation, AI-powered drug discovery, and strategic collaborations. Key strategic activities include mergers and acquisitions, licensing agreements, and sustained R&D investment aimed at expanding TROP-2 (搜索) therapies into early-line treatment settings and new indications.
Future Trajectory
Looking ahead, the report identifies expansion into early-line therapy, emerging market penetration, and novel combination regimens as the most significant growth opportunities. Continuous innovation in ADC technologies — including next-generation linker and payload designs — alongside the integration of real-world evidence into regulatory decision-making, is expected to sustain long-term market momentum despite existing challenges related to cost, safety, and regulatory complexity.